Trial Information

Summary: Do you suffer from knee pain due to osteoarthritis? If so, you may be eligible to take part in a clinical study testing the effectiveness of an investigational drug in treating knee pain due to osteoarthritis.

A randomized, double-blind clinical study wants to test the effectiveness of a pain medicine in order to treat knee pain due to osteoarthritis.

Patients cannot take part in the study if they have any previous diagnosis of psychosis, bipolar disorder, schizoaffective disorder or have a history of substance abuse or dependence within the past year, excluding nicotine and caffeine.

Patients must be at least 40 years of age and meet the American College of Rheumatology clinical and radiographic criteria for the diagnosis of OA of the knee with pain for at least 14 days per month for 3 months prior to study entry.

Your participation in this study is expected to last up to 15 weeks after screening is complete. Up to 230 subjects will be participating in this study at about 27 study sites in the United States.

Compensation for participation includes $31 per visit (up to a total of $186.00) to reimburse for transportation, parking, meal, or other expenses related to the study.

Patient Inclusion Criteria

• Patients must be at least 40 years with pain in the knee(s) for at least 14 days of each month for 3 months prior to study entry.
• Clinical diagnosis of osteoarthritis osteophytes with radiographic evidence and one of the following: >50 yrs or <30 minutes morning stiffness or Crepitus.
• Patient cannot have received intrarticular hyaluranoate or steroids, joint lavage, or invasive treatment to the index knee in past 6 months.
• No knee arthoscopy of index knee within past year.
• Subject must also be ambulatory

Patient Exclusion Criteria

• Patient will be excluded from the study if any of the following criteria apply:
• Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
• Have any previous diagnosis of psychosis, bipolar disorder, or schizoaffective disorder.
• Have major depressive disorder as determined using depression module of the Mini International Neuropsychiatric Interview (MINI).
• Have a history of substance abuse or dependence within the past year, excluding nicotine and caffeine.

For more information,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.